GHRP-6

5mg Vial

2 September 2026Updated 2 September 2026

GHRP-6

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for GHRP-6.

Create free account Member login

Full range of benefits for GHRP-6

Stimulates pulsatile growth hormone (GH) release via GHS‑R1a activation

Can raise circulating IGF‑1 levels indirectly through GH increase

Often increases appetite via ghrelin receptor (orexigenic effect)

May support lean mass preservation by promoting anabolic signaling

Has been reported to aid tissue repair and wound healing in studies

Shows anti‑inflammatory and anti‑apoptotic effects in preclinical work

May reduce muscle wasting in catabolic states (cachexia) in trials

Can influence energy balance and fat metabolism via GH/ghrelin pathways

May have cardio‑protective effects in animal and small human studies

Produces pulsatile GH release, differing from continuous recombinant GH exposure

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 15 known interactions

Synergistic(3)Compatible(4)Monitor(4)Avoid(4)

Not recommended for concurrent use

Recombinant human growth hormone (r-hGH)

Combining r-hGH with GHRP-6 produces additive GH/IGF-1 activity and increases risks of fluid retention, insulin resistance, and other GH excess effects, so careful evaluation is required.

Opioid analgesics

Opioids suppress the GH axis centrally and may blunt GHRP-6 efficacy, and clinicians should also consider combined effects on respiratory function and sedation when co-prescribed with other CNS depressants.

Active malignancy or recent cancer history

Because GHRP-6 stimulates the GH/IGF-1 axis, use with caution in patients with active or recent malignancy due to theoretical risk of promoting tumor growth and recurrence.

Pregnancy and breastfeeding

Safety of GHRP-6 in pregnancy and lactation is not established and modulation of the GH axis may pose fetal or neonatal risks, so avoid unless clearly justified.

All interaction categories

Synergistic (3)

CJC-1295 (without DAC): A GHRH analog that complements GHRP-6 by stimulating pituitary GH release via GHRH receptors, producing greater pulsatile GH secretion when combined.
Sermorelin: A GHRH peptide that acts synergistically with GHRP-6 through dual GHRH and ghrelin-receptor stimulation to augment overall GH release.
Arginine: An amino acid that transiently suppresses somatostatin and can potentiate GH secretion when administered with GHRP-6.

Compatible (4)

Metformin: An antihyperglycemic agent with no direct pharmacokinetic interaction with GHRP-6, but routine glycaemic monitoring is advised.
Levothyroxine: Thyroid hormone replacement does not directly interact with GHRP-6, though maintaining euthyroid status supports optimal GH axis function.
Statins (e.g., atorvastatin): Lipid-lowering agents have no known direct interaction with GHRP-6 and are generally neutral when coadministered.
Multivitamin/mineral supplementation: Standard vitamin and mineral supplements have no documented interactions with GHRP-6 and are considered compatible.

Monitor (4)

Insulin and insulin secretagogues (e.g., sulfonylureas): Monitor blood glucose closely because GHRP-6 increases appetite and GH-mediated insulin resistance can alter glycaemic control.
Exogenous IGF-1 (mecasermin): Monitor IGF-1 levels and glucose because combined IGF-1 and GHRP-6 effects increase hypoglycaemia risk and alter GH axis feedback.
Systemic glucocorticoids: Monitor clinical response and GH-axis biomarkers because glucocorticoids blunt GH secretion and may reduce GHRP-6 efficacy or require dose adjustments.
GLP-1 receptor agonists (e.g., liraglutide): Monitor appetite and glycaemic metrics as GLP-1 agonists reduce appetite and affect glucose control, potentially opposing or modifying GHRP-6 effects.

Avoid (4)

Recombinant human growth hormone (r-hGH): Combining r-hGH with GHRP-6 produces additive GH/IGF-1 activity and increases risks of fluid retention, insulin resistance, and other GH excess effects, so careful evaluation is required.
Opioid analgesics: Opioids suppress the GH axis centrally and may blunt GHRP-6 efficacy, and clinicians should also consider combined effects on respiratory function and sedation when co-prescribed with other CNS depressants.
Active malignancy or recent cancer history: Because GHRP-6 stimulates the GH/IGF-1 axis, use with caution in patients with active or recent malignancy due to theoretical risk of promoting tumor growth and recurrence.
Pregnancy and breastfeeding: Safety of GHRP-6 in pregnancy and lactation is not established and modulation of the GH axis may pose fetal or neonatal risks, so avoid unless clearly justified.